[ad_1]
Sanofi CEO Paul Hudson has said that a COVID-19 vaccine candidate the company is developing will not be ready in 2021.
“This vaccine will not be ready this year, but it could be useful at a later stage especially if the fight against the variants were to continue”, Reuters reported Hudson told French newspaper Le Journal du Dimanche.
The CEO gave no further details, according to the media.
The Hill has contacted the company for comment.
Sanofi has joined forces with the American company Translate Bio Last june to develop the vaccine based on mRNA technology. Vaccines from Pfizer / BioNTech and Moderna – both of which have been cleared for emergency use in the United States – also use this technology.
Reuters reported that clinical trials for the company’s vaccine were scheduled to begin this quarter, and Sanofi said in December that “the first potential approval” of the vaccine was in the second half of 2021.
Sanofi announced in december that interim results from a phase 1/2 clinical trial of a separate vaccine he is developing with UK-based GlaxoSmithKline (GSK) showed the candidate to have a weak immune response in the elderly. At the time, the company said the weak immune response could be due to insufficient concentration of the antigen.
The company plans to begin a Phase 2b trial of this vaccine this month, a move that will delay its availability in the second half of 2021.
The news comes after Sanofi’s announcement in at the end of January that it will help Pfizer and BioNTech produce doses of their vaccine from its facilities in Frankfurt, Germany, starting this summer.
[ad_2]
Source link